Cholestasis - A Pipeline Analysis Report 2018 by Technavio | Financial Buzz

Cholestasis – A Pipeline Analysis Report 2018 by Technavio

has announced their latest pipeline analysis report on the cholestasis
market. The report includes a detailed analysis of the pipeline
molecules under investigation within the defined data collection period
to treat cholestasis.

This press release features multimedia. View the full release here:

Technavio has published a new report on the drug development pipeline for cholestasis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)

This report presents a detailed analysis of the market, including
regulatory framework, drug development strategies, recruitment
strategies, and key companies that are expected to play an essential
role in the growth of the market in the coming years.

This report is available at a USD 1,000 discount for a limited time
only: View
market snapshot before purchasing

Cholestasis: Market overview

Cholestasis can be defined as the reduction in the flow of bile due to
the impaired secretion of bile from hepatocytes or because of an
obstruction in the flow of bile through intrahepatic or extrahepatic
bile ducts. The symptoms of cholestasis include jaundice, light-colored
stools, dark urine, and generalized itchiness. Jaundice develops due to
the excess bilirubin deposition in the skin, and dark urine can be
observed due to the excess bilirubin excretion from kidneys.

According to a senior analyst at Technavio for research on infectious
and rare diseases, “Stools may become light colored as the bilirubin
passage into the intestine gets blocked, stopping it from being
eliminated from the body through stools. Excess fat may be present in
stools as bile cannot enter the intestine to digest the fat present in
the diet.”

Cholestasis: Segmentation analysis

This market research report segments the cholestasis market based on
therapies employed that includes monotherapy and undisclosed, RoA (oral,
intravenous, subcutaneous and undisclosed), therapeutic modalities
(small molecules, microbiome, monoclonal antibody, protein and
undisclosed), targets for drugs under development (sodium-bile acid
cotransporter, FXR, PPAR, CD40, chemokine receptor antagonist, FGF,
NOX1/4, and undisclosed), MoA (sodium-bile acid cotransporter-inhibitor,
FXR agonist, PPAR agonist, CD40 inhibitor, CCR2/CCR5 antagonist, FGF
modulator, NOX1/4 inhibitor, and undisclosed), drugs under development
(discovery, pre-clinical, phase I/II, phase II, phase II/III, and phase
III), and recruitment status (recruiting, not yet recruiting, completed,
and NA). It provides an in-depth analysis of the prominent factors
influencing the market, including drivers, opportunities, trends, and
industry-specific challenges.

Looking for more information on this market? Request
a free sample report

Technavio’s sample reports are free of charge and contain multiple
sections of the report such as the market size and forecast, drivers,
challenges, trends, and more

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

Drug Development Strategies

Recruitment Strategies

Key Companies

Discontinued or Dormant Molecules

About Technavio

is a leading global technology research and advisory company. Their
research and analysis focuses on emerging market trends and provides
actionable insights to help businesses identify market opportunities and
develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists
of more than 10,000 reports and counting, covering 800 technologies,
spanning across 50 countries. Their client base consists of enterprises
of all sizes, including more than 100 Fortune 500 companies. This
growing client base relies on Technavio’s comprehensive coverage,
extensive research, and actionable market insights to identify
opportunities in existing and potential markets and assess their
competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team

View source version on